SLC5A1 and cystic fibrosis: Because the promoting effect appears to be CFTR independent, SGLT1 inhibitor drugs such as Sota may serve as a candidate “bridge” drug to treat CF patients (e.g., those of class I mutations) who currently do not benefit from Trikafta or any other drugs.